Overview

CMS’s review of plan formularies will ensure that plans offer a comprehensive array of drugs that reflects best practices in the pharmacy industry, as well as current treatment standards. We expect plan formularies and benefit designs to include the full range of treatment options and, at the same time, reflect drug benefit management tools that are proven and in widespread use in prescription drug plans today. Our goal is to ensure beneficiaries receive clinically appropriate medications at the lowest possible cost. In reaching this goal, we also need to acknowledge the specific needs of individuals who are already stabilized on certain drug regimens. In addition, it is important to recognize the needs of new full-benefit dual eligibles who may be auto-enrolled in a prescription drug plan and who, despite education and outreach efforts on the changing nature of their drug coverage under the Medicare drug benefit, may be unaware of the impact of the prescription drug plan’s formulary or utilization management practices on their existing drug regimens.

We believe that a requirement for an appropriate transition process for new enrollees balances the protection of certain vulnerable populations with the flexibility necessary for Part D plans to develop a benefit design that promotes beneficiary choice and affordable access to medically necessary drugs. We will review each plan sponsor’s transition process as part of our plan benefit design review.

To address the needs of individuals who are stabilized on certain drug regimens, Part D plans are required to establish an appropriate transition process for new enrollees who are transitioning to a Part D plan from other prescription drug coverage – including other Part D plans – and whose current drug therapies may not be included in their new Part D plan’s formulary. Plan transition processes must address situations in which enrollees are stabilized on formulary drugs that require prior authorization or step therapy under a plan’s utilization management rules. Finally, transition processes must address unplanned transitions as individuals change treatment settings due to changes in level of care.

Based on our experience with implementing the Part D benefit in 2006 – and in order to ensure the smoothest possible transition for new plan enrollees in 2007 – this document establishes a minimum set of proposed standards for a Part D sponsor transition process. These minimum standards specify the components of a transition process beyond simply the assurance of a temporary supply of non-formulary drugs or a transition period constituting a particular length of time. These proposed standards are based on policy clarifications provided to Part D plans in early 2006, but we emphasize that these standards are minimums and that plans are encouraged to go beyond these minimum requirements – particularly for enrollees with extenuating circumstances.

We welcome comments on all aspects of our proposed minimum standards for a transition process for Part D plans. Please send your comments to PartDformularies@cms.hhs.gov no later than Monday, March 6, 2006 at 5 p.m. EST for our consideration in drafting our final transition process requirements for Part D sponsors.
process requirements for 2007. We anticipate requiring plans to submit their transition processes for 2007 to PartDformularies@cms.hhs.gov by Monday, May 1, 2006 at 5 p.m. EST.

I. General Transition Process Requirements

In creating standards for a transition process, we have attempted to balance safeguards for a smooth transition process for plan enrollees with maximum flexibility for plan sponsors in managing their prescription drug benefit offerings. A transition process is necessary with respect to: (1) the transition of new enrollees into prescription drug plans on January 1, 2007 following the 2006 annual coordinated election period; (2) the transition of newly eligible Medicare beneficiaries from other coverage in 2007; (3) the transition of individuals who switch from one plan to another after January 1, 2007; (4) enrollees residing in long-term care (LTC) facilities, and (5) unplanned transitions as individuals change treatment settings due to changes in level of care.

In addition, transition process requirements will be applicable to both: (1) Part D drugs that are not on a plan’s formulary, and (2) Part D drugs that are on a plan’s formulary but require prior authorization or step therapy under a plan's utilization management rules, since a formulary drug whose access is restricted via utilization management requirements is essentially equivalent to a non-formulary Part D drug to the extent that the relevant utilization management requirements are not met for a particular enrollee.

P&T Committee Role

At a minimum, a transition process will address procedures for medical review of non-formulary drug requests and, when appropriate, a process for switching new Part D plan enrollees to therapeutically appropriate formulary alternatives failing an affirmative medical necessity determination. We will look to transition process submissions for assurances that a plan’s pharmacy and therapeutics (P&T) committee will review and provide recommendations regarding the procedures for medical review of non-formulary drug requests. P&T committee involvement will help ensure that transition decisions appropriately address situations involving enrollees stabilized on drugs that are not on the plan’s formulary (or that are on the formulary but require prior authorization or step therapy under a plan's utilization management requirements) and which are known to have risks associated with any changes in the prescribed regimen.

Temporary One-Time Fills

A plan’s transition process must address situations in which an individual first presents at a participating pharmacy with a prescription for a drug that is not on the formulary, unaware of what is covered by the plan or of the plan’s exception process to provide access to Part D drugs that are not covered. This may be particularly true for full-benefit dual eligible beneficiaries who are auto-enrolled in a plan and who do not make an affirmative choice based on review of a plan’s benefit relative to their existing medication needs. Plans must have systems capabilities that allow them to provide a one-time, temporary supply of non-formulary Part D drugs (including Part D drugs that are on a plan’s formulary but require prior authorization or step therapy under a plan’s utilization management rules) in order to accommodate the immediate
needs of an enrollee, as well as to allow the plan and/or the enrollee sufficient time to work out
with the prescriber an appropriate switch to a therapeutically equivalent medication or the
completion of an exception request to maintain coverage of an existing drug based on medical
necessity reasons.

A plan may charge cost-sharing for a temporary supply of drugs provided under its transition
process. Copayments for low-income subsidy (LIS) eligibles are limited to the statutory
maximum copayment amounts. For non-LIS enrollees, a plan must charge cost-sharing based on
one of its approved drug cost-sharing tiers (if the plan has a tiered benefit design), and this cost-
sharing must be consistent with cost-sharing that the plan would charge for non-formulary drugs
approved under a coverage exception.

Transition Timeframes

In order to balance the need for a smooth transition with plans’ ability to effectively manage their
benefits, we believe it makes sense to both limit and define the amount of time during which a
transition process is applicable to new enrollees. To that end, plans will be required to provide a
temporary supply fill anytime during the first 90 days of a beneficiary’s enrollment in a plan.
Because it is possible that beneficiaries transitioning from other prescription drug coverage will
have obtained extended (e.g., 90-day) supplies of maintenance drugs prior to the last effective
date of their previous coverage, plans must provide a temporary 30-day fill (unless the enrollee
presents with a prescription written for less than 30 days) when a beneficiary presents at a
pharmacy to request a refill of a non-formulary drug (including Part D drugs that are on a plan’s
formulary but require prior authorization or step therapy under a plan’s utilization management
rules) within the first 90 days of their coverage under the new plan. Since certain enrollees may
join a plan at any time during the year, this requirement will apply beginning on an enrollee’s
first effective date of coverage, and not only to the first 90 days of the contract year.

Edits for Transition Supplies

One of our most important goals for a transition process is to ensure that a new enrollee is able to
leave a pharmacy with a temporary supply of non-formulary Part D drugs without unnecessary
delays. To this end, plans should used sound business and clinical decision-making with regard
to the establishment of certain edits (e.g., safety edits) associated with temporary supplies of
non-formulary Part D drugs at the point of sale. In addition, to the extent that plans choose to
establish any safety edits for certain transition drugs, they must be able to resolve those edits at
the point of sale. As part of their transition process submissions to CMS, plans should describe
any edits on transition drugs and their process for resolving those edits at the point of sale.

We note that although Part D plans may implement quantity limits for safety purposes or drug
utilization edits that are based upon approved product labeling during a beneficiary’s transition
period, to the extent that the prescription is dispensed for less than the written amount due to the
edit, plans must provide refills for that transition supply (up to a 30-day supply in a retail setting
and a 90-day supply in a long-term care setting). For example, if a beneficiary presents at a retail
pharmacy with a prescription for one tablet per day for 30 days and a plan has a quantity limit
edit in place that limits the days supply to 14 per prescription for safety purposes, the beneficiary
would receive a 14-day supply (consistent with the safety edit). At the conclusion of the 14-day supply, the beneficiary should be entitled to another 14-day supply while he/she continues to pursue an exception with the Part D plan, or a switch to a therapeutic alternative that is on the plan’s formulary.

**New Prescriptions versus Ongoing Medication Therapy**

We are aware that it may be difficult for plans to distinguish between new prescriptions for non-formulary Part D drugs and refills for ongoing medication therapy involving non-formulary Part D drugs. For example, some new enrollees may need to switch pharmacies when they enroll in a new Part D plan (or when they enroll in Part D for the first time) and, depending on state law, their prescriptions may not transfer from pharmacy to pharmacy. In other words, some enrollees may need to present at their new network pharmacy with a new prescription for use at that pharmacy, even if that prescription is for ongoing medication therapy. We recognize that it may be difficult for plans to distinguish between ongoing medication therapy and a brand-new prescription for a non-formulary Part D drug. If a plan is unable to make this distinction at the point of sale, it will be required to apply all transition process standards specified by CMS in this document to a new prescription for a non-formulary Part D drug; in other words, a brand-new prescription for a non-formulary drug will not be treated any differently than an ongoing prescription for a non-formulary drug.

**Transition Notices**

A successful transition process is contingent upon informing enrollees and their caretakers about their options for ensuring that enrollees’ medical needs are safely accommodated within a Part D plan’s formulary. An enrollee who receives a temporary supply of a non-formulary Part D drug at a network pharmacy might simply assume that, by virtue of filling his or her prescription, that the plan will cover that drug for the remainder of the plan year. For this reason, plans must provide enrollees with appropriate notice regarding their transition process within a reasonable amount of time after providing a temporary supply of non-formulary Part D drugs (including Part D drugs that are on a plan’s formulary but require prior authorization or step therapy under a plan’s utilization management rules). Plans must also add an edit code to their systems that serves to inform a pharmacy that a fill for a particular drug is a transition supply rather than a formulary drug.

This notice must include the following elements: (1) an explanation of the temporary nature of the transition supply an enrollee has received; (2) instructions for working with the plan sponsor and the enrollee’s prescriber to identify appropriate therapeutic alternatives that are on the plan’s formulary; (3) an explanation of the enrollee’s right to request a formulary exception; and (4) a description of the procedures for requesting a formulary exception. We are considering requiring that this notice be sent to each affected within 72 hours of the temporary fill. We believe this turnaround is necessary in order to provide an affected enrollee with sufficient time to work with his or her prescriber to switch to a therapeutically equivalent drug that is on the plan’s formulary or to process an exceptions request. We are also considering requiring that this notice be sent to each enrollee via U.S. mail. Such standard would be consistent with our requirement that other beneficiary communications, including formulary change notices and explanations of benefits, be
sent via U.S. mail. We particularly request feedback on our proposed standard elements for transition notices to ensure these requirements appropriately balance beneficiary needs and plans’ ability to effectively manage their benefits.

Public Notice of Transition Process

As a general matter, we believe plan sponsors must make general information about their transition processes available to beneficiaries in a manner similar to information provided on formularies and benefit design. It is likely that individuals will base their decision on which prescription drug best meets their needs on a variety of factors. Matching their current medication list with a Part D plan’s formulary may be only one factor in the decision making process. Other factors, such as cost issues and inclusion of the retail pharmacy that they are most familiar with in the plan’s network, may bear more weight in the final decision-making process. Having information about a plan’s transition process in plan enrollment materials and websites, as well as on the Medicare Prescription Drug Plan Finder, may reassure beneficiaries that there will be procedures in place to assist them in switching to therapeutic alternatives or in obtaining a formulary exception where appropriate. It will also serve to educate advocates and other interested third parties – for example, state Medicaid agencies – about plan transition processes.

We are considering the feasibility of requiring that plan transition process information be made available on the Medicare Prescription Drug Finder, either via a feed from HPMS to the Plan Finder or via a link from Plan Finder to individual plan websites. We solicit feedback on these and other approaches for providing beneficiaries and other stakeholders with information about plan transition processes.

II. Transition Process in the Retail Setting

The minimum transition process standards described in Section I will apply to beneficiaries obtaining their drugs in a retail setting (or via home infusion, safety-net, or I/T/U pharmacies). However, we clarify that, in the retail setting, the one-time, temporary supply of non-formulary Part D drugs – including Part D drugs that are on a plan’s formulary but require prior authorization or step therapy under a plan’s utilization management rules – must be for at least 30 days of medication, unless the prescription is written by a prescriber for less than 30 days. Plans should note that, outside the long-term care setting, such a temporary fill may be a one-time fill only.

III. Transition Process in the LTC Setting

It is important that the transition process take into account the unique needs of residents of LTC facilities who enroll in a new Part D plan. Residents of LTC facilities are more likely to be receiving multiple medications for which simultaneous changes could significantly impact the condition of the enrollee. In addition, given that a large proportion of LTC facility residents may be dually eligible for both Medicare and full Medicaid benefits, and could be auto-enrolled into the plan without making an affirmative selection based on the individual’s existing treatment
needs, it is critical that the transition process address access to medications at the filling of the first prescription. Plan sponsors will need to ensure that LTC pharmacies in the plan’s network that have relationships with LTC facilities work with those facilities prior to the effective date of enrollment to ensure a seamless transition of the facility’s residents.

**Transition Period Immediately After Enrollment for LTC Facility Residents**

The minimum transition process standards described in Section I will apply to beneficiaries obtaining their drugs in a long-term care setting. As in the retail setting, the temporary supply of non-formulary Part D drugs – including Part D drugs that are on a plan's formulary but require prior authorization or step therapy under a plan's utilization management rules – for a new enrollee in a LTC facility must be for at least 30 days (unless the prescription is written for less than 30 days). However, unlike in the retail setting, plans must honor multiple fills of non-formulary Part D drugs, including Part D drugs that are on a plan’s formulary but require prior authorization or step therapy under a plan’s utilization management rules, as necessary during the entire length of the 90-day transition period.

**Emergency Supply for Current Enrollees**

Since, as a matter of general practice, LTC facility residents must receive their medications as ordered without delay, Part D plans must cover an emergency supply of non-formulary Part D drugs for LTC facility residents as part of their transition process. During the first 90 days after a beneficiary's enrollment, he or she will receive a transition supply via the process described above. However, to the extent that an enrollee in a long-term care setting is outside his or her 90-day transition period, the plan must still provide an emergency supply of non-formulary Part D drugs – including Part D drugs that are on a plan's formulary but require prior authorization or step therapy under a plan's utilization management rules – while an exception is being processed. This policy was in effect during the 2006 calendar year, although we never specified a days supply requirement for such emergency fill. We recommend requiring that the emergency supply provided to current enrollees in a LTC setting be for at least 30 days (unless the prescription is written for less than 30 days) for consistency with the general transition process requirements. This requirement would accommodate a situation in which a current enrollee is admitted to a nursing home and experiences an early refill edit from his or her plan which prevents the enrollee from getting necessary medications after admission. We request comments on this proposed requirement.

**III. Current Enrollee Transitions**

In addition to circumstances impacting new enrollees who may enter a plan with a medication list that contains non-formulary Part D drugs, other circumstances exist in which unplanned transitions for current enrollees could arise and in which prescribed drug regimens may not be on plan formularies. These circumstances usually involve level of care changes in which a beneficiary is changing from one treatment setting to another. For example, beneficiaries who enter LTC facilities from hospitals are sometimes accompanied by a discharge list of medications from the hospital formulary, with very short term planning taken into account (often
under 8 hours). Similar situations may exist, for example, for beneficiaries who are discharged from a hospital to a home; for beneficiaries who end their skilled nursing facility Medicare Part A stay (where payments include all pharmacy charges) and who need to revert to their Part D plan formulary; for beneficiaries who give up hospice status to revert to standard Medicare Part A and B benefits; for beneficiaries who end a long-term care facility stay and return to the community; and for beneficiaries who are discharged from psychiatric hospitals with medication regimens that are highly individualized.

For these unplanned transitions, beneficiaries and providers must clearly avail themselves of plan exceptions and appeals processes. We have streamlined the grievance, coverage determination, and appeals process requirements in order to ensure that beneficiaries receive quick determinations regarding the medications they need. In all cases, we make it clear that a Part D plan sponsor is required to make coverage determinations and redeterminations as expeditiously as the enrollee’s health condition requires.

However, even with these protections, there may exist some period of time in which beneficiaries have a temporary gap in coverage while an exception is processed. For this reason, plan transition processes must ensure that the same transition processes described in this guidance are applied to current enrollees with level of care changes. We solicit comments on this proposed standard, including how such level of care changes could be flagged in plans' systems to trigger an override such that a transition supply is provided to an enrollee affected by such a change.